Dr Reddy’s Q1 FY27 Results: Net Profit Drops 8% to ₹1,290 Crore as US Revenues Decline

Dr. Reddy’s Laboratories reported Q1 FY27 net profit of ₹1,290 crore, down 8% year-on-year from ₹1,392 crore.

North American generics revenue fell 7% to ₹3,120 crore due to price erosion on molecules like Revlimid (lenalidomide).

Consolidated revenue from operations declined 0.3% to ₹7,650 crore.

India business grew 11% to ₹1,480 crore, driven by consumer health ventures and new brand launches.

R&D expenses rose to ₹610 crore (8% of revenue) to support biosimilars and complex generics pipeline.